GTX Stock Price, News & Analysis (NASDAQ:GTXI)

$12.65 0.15 (1.20 %)
(As of 01/19/2018 06:04 AM ET)
Previous Close$12.50
Today's Range$12.31 - $12.70
52-Week Range$2.73 - $13.35
Volume55,300 shs
Average Volume60,558 shs
Market Capitalization$269.27 million
P/E Ratio-7.19
Dividend YieldN/A
Beta1.77

About GTX (NASDAQ:GTXI)

GTX logoGTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive GTXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700

Debt

Debt-to-Equity RatioN/A
Current Ratio6.01%
Quick Ratio6.01%

Price-To-Earnings

Trailing P/E Ratio-7.1875
Forward P/E Ratio-7.86
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.25 per share
Price / Book10.12

Profitability

Trailing EPS($1.76)
Net Income$-17,720,000.00
Net MarginsN/A
Return on Equity-125.79%
Return on Assets-99.26%

Miscellaneous

Employees26
Outstanding Shares21,540,000

GTX (NASDAQ:GTXI) Frequently Asked Questions

What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) issued its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.25. View GTX's Earnings History.

When will GTX make its next earnings announcement?

GTX is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for GTX.

Where is GTX's stock going? Where will GTX's stock price be in 2018?

2 brokers have issued twelve-month price targets for GTX's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate GTX's stock price to reach $17.00 in the next year. View Analyst Ratings for GTX.

Who are some of GTX's key competitors?

Who are GTX's key executives?

GTX's management team includes the folowing people:

  • Robert James Wills Ph.D., Executive Chairman of the Board (Age 62)
  • Marc S. Hanover, Chief Executive Officer, Director (Age 53)
  • Jason T. Shackelford, Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer (Age 39)
  • Henry P. Doggrell Sr., Vice President, Chief Legal Officer, Secretary (Age 66)
  • Diane C Young M.D., Vice President, Chief Medical Officer
  • Joseph R. Hyde III, Lead Director (Age 74)
  • Garry Neil M.D., Director
  • Michael G. Carter M.D., Independent Director (Age 76)
  • J. Kenneth Glass, Independent Director (Age 68)
  • Kenneth S. Robinson M.D., Independent Director (Age 60)

How do I buy GTX stock?

Shares of GTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GTX's stock price today?

One share of GTX stock can currently be purchased for approximately $12.65.

How big of a company is GTX?

GTX has a market capitalization of $269.27 million. The biopharmaceutical company earns $-17,720,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. GTX employs 26 workers across the globe.

How can I contact GTX?

GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]


MarketBeat Community Rating for GTX (GTXI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GTX (NASDAQ:GTXI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AHold
Consensus Rating Score: 3.003.00N/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.00$17.00N/A$1.00
Price Target Upside: 52.88% upside52.88% upsideN/A28.21% upside

GTX (NASDAQ:GTXI) Consensus Price Target History

Price Target History for GTX (NASDAQ:GTXI)

GTX (NASDAQ:GTXI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$17.00N/AView Rating Details
11/9/2017Stifel NicolausInitiated CoverageBuy -> BuyN/AView Rating Details
9/9/2016Jefferies GroupReiterated RatingHold$1.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

GTX (NASDAQ:GTXI) Earnings History and Estimates Chart

Earnings by Quarter for GTX (NASDAQ:GTXI)

GTX (NASDAQ GTXI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.48)N/AView Earnings Details
11/14/2017Q3 2017($0.28)($0.53)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.40)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.39)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.57)($0.44)ViewN/AView Earnings Details
11/3/2016Q3($0.05)($0.05)ViewN/AView Earnings Details
8/9/2016Q2($0.05)($0.04)ViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details
3/3/2016Q415($0.10)($0.04)ViewListenView Earnings Details
10/29/2015Q315($0.06)($0.04)ViewListenView Earnings Details
8/6/2015Q215($0.04)($0.03)ViewListenView Earnings Details
5/8/2015Q1($0.04)($0.04)ViewListenView Earnings Details
3/4/2015Q314($0.07)($0.05)ViewListenView Earnings Details
11/10/2014Q214($0.10)($0.06)ViewListenView Earnings Details
8/5/2014Q2($0.11)($0.15)ViewN/AView Earnings Details
5/8/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/4/2014Q413($0.13)($0.12)ViewListenView Earnings Details
11/12/2013Q313($0.21)($0.14)ViewListenView Earnings Details
7/19/2013Q2 2013($0.22)($0.20)ViewN/AView Earnings Details
5/3/2013Q1 2013($0.21)($0.20)ViewListenView Earnings Details
2/21/2013Q4 2012($0.21)($0.17)ViewListenView Earnings Details
11/8/2012Q312($0.17)$0.12$1.93 millionViewN/AView Earnings Details
8/8/2012($0.17)($0.17)ViewN/AView Earnings Details
5/8/2012($0.17)($0.18)ViewN/AView Earnings Details
2/21/2012($0.17)($0.17)ViewN/AView Earnings Details
11/4/2011($0.18)($0.15)ViewN/AView Earnings Details
8/9/2011($0.19)($0.21)ViewN/AView Earnings Details
5/9/2011($0.13)($0.05)ViewN/AView Earnings Details
2/24/2011($0.16)($0.16)ViewN/AView Earnings Details
11/9/2010Q3 2010($2.90)($2.35)ViewN/AView Earnings Details
8/9/2010Q2 2010($2.70)($3.55)ViewN/AView Earnings Details
5/4/2010Q1 2010$11.60$12.17ViewN/AView Earnings Details
3/15/2010Q4 2009($3.50)($3.00)ViewN/AView Earnings Details
11/9/2009Q3 2009($3.40)($3.52)ViewN/AView Earnings Details
8/10/2009Q2 2009($3.60)($3.09)ViewN/AView Earnings Details
5/11/2009Q1 2009($3.80)($3.10)ViewN/AView Earnings Details
2/17/2009Q4 2008($3.90)($3.81)ViewN/AView Earnings Details
11/6/2008Q3 2008($4.30)($3.28)ViewN/AView Earnings Details
8/5/2008Q2 2008($3.80)($3.66)ViewN/AView Earnings Details
5/12/2008Q1 2008($3.10)($3.52)ViewN/AView Earnings Details
2/19/2008Q4 2007($3.40)($3.64)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GTX (NASDAQ:GTXI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.68 EPS

Dividends

Dividend History for GTX (NASDAQ:GTXI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GTX (NASDAQ GTXI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.20%
Institutional Ownership Percentage: 11.57%
Insider Trades by Quarter for GTX (NASDAQ:GTXI)
Insider Trades by Quarter for GTX (NASDAQ:GTXI)

GTX (NASDAQ GTXI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Henry Patton DoggrellVPSell4,965$11.33$56,253.4554,804View SEC Filing  
1/5/2018Jason T ShackelfordInsiderSell3,090$11.33$35,009.7031,111View SEC Filing  
1/5/2018Marc Steven HanoverCEOSell7,309$11.33$82,810.97129,990View SEC Filing  
10/14/2016Peak Foundation PyramidMajor ShareholderBuy7,716,049$0.81$6,249,999.6938,249,528View SEC Filing  
6/16/2016Robert James WillsChairmanBuy100,000$0.65$65,000.001,200,000View SEC Filing  
3/1/2016J Kenneth GlassDirectorBuy44,000$0.60$26,400.00183,768View SEC Filing  
1/26/2016Marc Steven HanoverCEOBuy4,000$0.65$2,600.001,257,224View SEC Filing  
1/25/2016Marc Steven HanoverCEOBuy12,813$0.63$8,072.191,253,224View SEC Filing  
1/19/2016Marc Steven HanoverCEOBuy25,000$0.50$12,500.001,240,411View SEC Filing  
1/14/2016Marc Steven HanoverCEOBuy25,000$0.49$12,250.001,193,311View SEC Filing  
12/24/2015J Kenneth GlassDirectorBuy100$0.79$79.00139,768View SEC Filing  
12/22/2015J Kenneth GlassDirectorBuy1,907$0.78$1,487.46139,068View SEC Filing  
12/21/2015J Kenneth GlassDirectorBuy39,900$0.78$31,122.00137,761View SEC Filing  
5/19/2015J Kenneth GlassDirectorBuy24,500$1.25$30,625.00View SEC Filing  
5/14/2015Robert James WillsChairmanBuy46,140$0.96$44,294.40View SEC Filing  
5/8/2015Henry Patton DoggrellVPBuy25,477$0.80$20,381.60View SEC Filing  
5/8/2015Robert James WillsChairmanBuy50,000$0.80$40,000.00View SEC Filing  
4/22/2015J Kenneth GlassDirectorBuy10,000$0.72$7,200.00View SEC Filing  
4/21/2015J Kenneth GlassDirectorBuy11,608$0.71$8,241.68View SEC Filing  
4/15/2015J Kenneth GlassDirectorBuy3,300$0.72$2,376.00View SEC Filing  
4/10/2015J Kenneth GlassDirectorBuy16,400$0.67$10,988.00View SEC Filing  
9/23/2014Marc Steven HanoverCEOBuy5,000$0.75$3,750.00View SEC Filing  
9/17/2014Marc Steven HanoverCEOBuy10,000$0.74$7,400.00View SEC Filing  
8/21/2014Marc Steven HanoverCEOBuy20,000$1.00$20,000.00View SEC Filing  
8/19/2014Marc Steven HanoverCEOBuy10,000$1.01$10,100.00View SEC Filing  
8/8/2014Henry Patton DoggrellVPBuy10,000$0.97$9,700.00View SEC Filing  
8/8/2014Marc Steven HanoverCEOBuy30,000$0.93$27,900.00View SEC Filing  
8/7/2014Jason T ShackelfordInsiderBuy10,000$0.92$9,200.00View SEC Filing  
8/7/2014Marc Steven HanoverCEOBuy30,000$0.92$27,600.00View SEC Filing  
6/6/2014James T DaltonVPSell72,883$1.30$94,747.90View SEC Filing  
3/21/2014Jack Schulermajor shareholderSell1,192,251$1.84$2,193,741.846,165,261View SEC Filing  
8/22/2013Jack Schulermajor shareholderBuy93,777$1.36$127,536.727,357,512View SEC Filing  
8/21/2013Jack Schulermajor shareholderBuy309,591$1.42$439,619.227,263,735View SEC Filing  
7/9/2013Mark Edward MostellerCFOSell17,000$6.99$118,830.00View SEC Filing  
1/17/2013James T DaltonVPSell20,000$5.20$104,000.00View SEC Filing  
12/14/2012Timothy R G SearDirectorBuy50,000$4.33$216,500.00View SEC Filing  
8/27/2012J Kenneth GlassDirectorBuy10,000$3.76$37,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GTX (NASDAQ GTXI) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate GTx, Inc. (GTXI) Will Post Earnings of -$0.39 Per ShareZacks: Brokerages Anticipate GTx, Inc. (GTXI) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - January 17 at 3:12 AM
Jason T. Shackelford Sells 3,090 Shares of GTx, Inc. (GTXI) StockJason T. Shackelford Sells 3,090 Shares of GTx, Inc. (GTXI) Stock
www.americanbankingnews.com - January 9 at 7:56 PM
GTx, Inc. (GTXI) VP Sells $56,253.45 in StockGTx, Inc. (GTXI) VP Sells $56,253.45 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM
GTx, Inc. (GTXI) CEO Sells $82,810.97 in StockGTx, Inc. (GTXI) CEO Sells $82,810.97 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM
Analysts Expect GTx, Inc. (GTXI) to Post ($0.39) EPSAnalysts Expect GTx, Inc. (GTXI) to Post ($0.39) EPS
www.americanbankingnews.com - January 8 at 9:40 AM
BRIEF-GTX Inc Files For Mixed Shelf Offering Of Up To $150 MlnBRIEF-GTX Inc Files For Mixed Shelf Offering Of Up To $150 Mln
www.reuters.com - December 23 at 9:19 PM
 GTx, Inc. (GTXI) Receives Consensus Rating of "Strong Buy" from Brokerages GTx, Inc. (GTXI) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 23 at 11:40 AM
-$0.39 Earnings Per Share Expected for GTx, Inc. (GTXI) This Quarter-$0.39 Earnings Per Share Expected for GTx, Inc. (GTXI) This Quarter
www.americanbankingnews.com - December 14 at 7:16 AM
GTx, Inc. (GTXI) Expected to Announce Earnings of -$0.39 Per ShareGTx, Inc. (GTXI) Expected to Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - November 26 at 7:08 AM
Pre-Open Movers 11/21: (CLSN) (PANW) (SNSS) Higher; (CYTK) (QD) (SIG) Lower (more...)Pre-Open Movers 11/21: (CLSN) (PANW) (SNSS) Higher; (CYTK) (QD) (SIG) Lower (more...)
www.streetinsider.com - November 21 at 7:17 PM
GTx, Inc. (GTXI) Coverage Initiated by Analysts at Robert W. BairdGTx, Inc. (GTXI) Coverage Initiated by Analysts at Robert W. Baird
www.americanbankingnews.com - November 21 at 7:06 AM
GTx reports 3Q lossGTx reports 3Q loss
finance.yahoo.com - November 16 at 3:25 PM
GTx, Inc. (GTXI) Releases  Earnings Results, Misses Expectations By $0.25 EPSGTx, Inc. (GTXI) Releases Earnings Results, Misses Expectations By $0.25 EPS
www.americanbankingnews.com - November 15 at 12:54 PM
GTx Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsGTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 7:51 PM
 Analysts Set $16.00 Target Price for GTx, Inc. (GTXI) Analysts Set $16.00 Target Price for GTx, Inc. (GTXI)
www.americanbankingnews.com - November 11 at 9:24 PM
Analyzing GTx (GTXI) & Brainstorm Cell Therapeutics (BCLI)Analyzing GTx (GTXI) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 8 at 7:28 PM
GTx, Inc. to Participate in the Stifel 2017 Healthcare ConferenceGTx, Inc. to Participate in the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 8:37 AM
BRIEF-GTX Inc files for offering of up to 8.8 million shares of common stockBRIEF-GTX Inc files for offering of up to 8.8 million shares of common stock
www.reuters.com - October 20 at 11:07 PM
Analyzing GTx (GTXI) & Blueprint Medicines Corporation (BPMC)Analyzing GTx (GTXI) & Blueprint Medicines Corporation (BPMC)
www.americanbankingnews.com - October 8 at 6:16 PM
BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29
www.reuters.com - October 7 at 12:50 AM
GO Therapeutics appoints Dr. Robert J. Wills to Board of DirectorsGO Therapeutics appoints Dr. Robert J. Wills to Board of Directors
globenewswire.com - October 5 at 2:31 PM
GTx Announces Closing Of $48.5 Million Private PlacementGTx Announces Closing Of $48.5 Million Private Placement
www.thestreet.com - September 29 at 4:37 PM
BRIEF-GTx announces $48.5 million private placementBRIEF-GTx announces $48.5 million private placement
www.reuters.com - September 27 at 5:14 PM
Memphis drug developer announces $48.5 private placementMemphis drug developer announces $48.5 private placement
www.bizjournals.com - September 27 at 5:14 PM
GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare ConferenceGTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 26 at 11:23 AM
GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28 th in New York CityGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28 th in New York City
www.businesswire.com - September 23 at 6:50 PM
GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York CityGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
finance.yahoo.com - September 22 at 1:17 PM
GTx (GTXI) vs. Its Peers Financial ComparisonGTx (GTXI) vs. Its Peers Financial Comparison
www.americanbankingnews.com - September 19 at 12:48 AM
Comparing GTx (GTXI) and Its PeersComparing GTx (GTXI) and Its Peers
www.americanbankingnews.com - September 16 at 6:30 PM
GTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUIGTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - September 14 at 7:58 PM
GTxs (GTXI) Enobosarm Positive in Phase II, Shares DownGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
GTx's (GTXI) Enobosarm Positive in Phase II, Shares DownGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary IncontinenceGTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
finance.yahoo.com - September 14 at 4:00 AM
GTx, Inc. (GTXI) Releases  Earnings ResultsGTx, Inc. (GTXI) Releases Earnings Results
www.americanbankingnews.com - August 15 at 1:10 PM
GTx Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsGTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 7:38 PM
GTx reports 2Q lossGTx reports 2Q loss
finance.yahoo.com - August 14 at 7:38 PM
Astellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of DirectorsAstellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors
www.bizjournals.com - July 14 at 2:49 AM
GTx Discusses Key Goals with WSAGTx Discusses Key Goals with WSA
finance.yahoo.com - July 12 at 7:59 PM
GTxs (GTXI) Enobosarm Positive in Phase II Study; Shares UpGTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
www.zacks.com - June 15 at 12:03 AM
Veru Healthcare: The Merger And What Lies AheadVeru Healthcare: The Merger And What Lies Ahead
seekingalpha.com - June 13 at 11:09 AM
GTx Hikes on Treatment Test ResultsGTx Hikes on Treatment Test Results
www.baystreet.ca - June 13 at 11:09 AM
GTx, Inc. (GTXI) Releases Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with SUIGTx, Inc. (GTXI) Releases Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - June 13 at 11:09 AM
GTx Inc. (GTXI) Jumped To A 4-Month High On Study ResultsGTx Inc. (GTXI) Jumped To A 4-Month High On Study Results
www.rttnews.com - June 13 at 11:09 AM
Mid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike HigherMid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike Higher
feeds.benzinga.com - June 12 at 12:43 PM
GTxs enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarketGTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket
seekingalpha.com - June 12 at 8:28 AM
Drugmakers and biotechs increasingly view Trump as a business riskDrugmakers and biotechs increasingly view Trump as a business risk
www.bizjournals.com - May 19 at 10:06 AM
Biotech firms increasingly view Trump as a business riskBiotech firms increasingly view Trump as a business risk
www.bizjournals.com - May 17 at 5:34 PM
BRIEF-GTX reports Q1 net loss per share of $0.39BRIEF-GTX reports Q1 net loss per share of $0.39
www.reuters.com - May 16 at 11:27 AM
GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...
www.businesswire.com - May 12 at 6:14 PM
GTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular GeneticsGTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular Genetics
www.streetinsider.com - May 3 at 3:03 PM

SEC Filings

GTX (NASDAQ:GTXI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GTX (NASDAQ:GTXI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GTX (NASDAQ GTXI) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.